Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

News Releases

How Can Early-Stage Medical Device Companies Survive Market Turmoil?
May 23, 2020
Medical Device and Diagnostic Industry (MD+DI) David Hochman, founder and CEO of Orchestra BioMed, shares how the company's risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic. CLICK HERE FOR FULL ARTICLE
Daniel Burkhoff, MD, PhD, presented data from our MODERATO II double-blind, randomized study of BackBeat Cardiac Neuromodulation Therapy ™ at the 2020 Heart Rhythm Scientific Sessions online
May 8, 2020
Event:  2020 Heart Rhythm Scientific Sessions online Webcast:  HTTPS://CSLIDE-US.CTIMEETINGTECH.COM/HRS20/ATTENDEE/EPOSTER/POSTER/1407?Q=BURKHOFF
Orchestra BioMed™ Enhances Management Team with Appointment of Regulatory Affairs and Combination Product Expert Bob Laughner as Vice President, Regulatory Affairs
April 28, 2020
New Hope, PA - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Bob Laughner, an expert in global regulatory affairs for
Orchestra BioMed™ Secures $20 Million Financing Facility from Silicon Valley Bank
December 10, 2019
New York, NY – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank
Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress
December 5, 2019
New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in
Orchestra BioMed™ to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference
November 19, 2019
New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced David P. Hochman, chairman, CEO and founder, will present at the Canaccord Genuity MedTech
Orchestra BioMed™ Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
October 16, 2019
New Hope, PA – Orchestra BioMed ™ ,Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams.
Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure
September 28, 2019
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease
September 17, 2019
First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon in coronary in-stent restenosis granted in Q2 2019 New Hope, PA – Orchestra
Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension
September 4, 2019
Late-breaking BackBeat CNT ™  randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019 New Hope, PA – Orchestra BioMed ™ , Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page next ›
  • Last page last »
Displaying 11 - 20 of 40
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer